Fig. 5

Tagln2^−/− DCs did not optimally support T cell activation in vitro. a, c Differentiation (a), activation (b), and cytokine secretion (c) of Tagln2^−/− BM cells. WT or Tagln2^−/− BM cells were cultured with GM-CSF, and then, CD11c⁺ cell populations were examined at the indicated days (a). Differentiated CD11c⁺ cells were further activated with LPS or pOVA (323–339), plus OTII T cells. Activation markers (b) and cytokine production (c) were determined. d–f The cells from a were co-incubated with OTII CD4⁺ T cells in the presence of different doses of pOVA (323–339, 10⁻³–10¹ μg/mL), and then, T cell activation (CD69 and CD25 and IL-2, IL-4, and IFN-γ) was determined by flow cytometry and ELISA. g Schematic diagram of the experimental setup for G and H. Representative histogram showing the in vitro proliferation of OVA (257–264)-specific CD8⁺ T cells isolated from C57BL/6 mice administered with pOVA (257–264)-pulsed WT DCs or Tagln2^−/− DCs. Isolated CD3⁺ T cells were stained with CTV and co-incubated with pOVA (257–264)-pulsed WT DCs in vitro for 4 days. h From the supernatant of experiment g, IL-2 or IFN-γ production was determined at 24 h by ELISA. All data represent the mean of three experiments ± SEM. *P < 0.05; **P < 0.01